• Zelira's HOPE® 1 SPV secures US$32.98M before costs
• Zelira retains 39.70% interest in HOPE® 1 SPV
• SPV valuation post-money stands at US$65.96M
• Zelira to lodge interim financial statements post-fundraising
• SPV aims to initiate FDA clinical trial for HOPE® 1

Zelira Therapeutics Ltd announced the completion of definitive agreements to raise US$32.98M (before costs) into its HOPE® 1 Special Purpose Vehicle (SPV). Zelira retains a 39.70% interest in the SPV, which is valued at US$65.96M post-money, with Zelira's post-money interest valued at US$26.19M. The company plans to lodge its 31 December 2025 interim financial statements shortly after the fundraising closes and will seek reinstatement of its securities to quotation. Zelira and Thirdgate remain committed to closing the SPV fundraising and advancing the HOPE® clinical trial program. The SPV will focus on submitting an Investigational New Drug (IND) application to the FDA and initiating a Phase 1 clinical trial for HOPE® 1.

Zelira's HOPE® 1 SPV valuation post-money at US$65.96M

Zelira and Thirdgate remain committed to closing the SPV fundraising and advancing the HOPE® clinical trial program. The SPV will focus on submitting an Investigational New Drug (IND) application to the FDA and initiating a Phase 1 clinical trial for HOPE® 1.